AnaptysBio, Inc. (ANAB), a San Diego–based biotechnology company, has evolved sharply in recent quarters. After completing the spinoff of its First Tracks Biotherapeutics unit in April 2026, the company now operates primarily as a royalty-management business, focused on monetizing financial collaborations tied to GSK plc (GSK) and Vanda Pharmaceuticals (VNDA). With the stock trading near $49, the question is whether it can climb to a $75 stock price target.
I reviewed eight current, attributable analyst price targets, each tied to a named firm and a recent date. They are: H.C. Wainwright at $95 (October 2026), Piper Sandler at $93 (July 2026), Leerink Partners at $81 (September 2026), UBS at $76 (May 2026), Barclays at $75 (September 2026), Wedbush at $75 (March 2026), J.P. Morgan at $60 (September 2026, lowered from $70), and Truist Securities at $50 (March 2026).
The low-to-high range runs from $50 to $95, and the arithmetic mean is roughly $75.6, which I round to a clean $75 central target. That dispersion is unusually wide and is not a sign of error — it reflects genuinely different views on how much the company's royalty business is worth.
Most firms rate ANAB a Buy or Overweight, with Truist's Hold and lower $50 target the clearest cautious stance. Bulls, such as H.C. Wainwright's Joseph Pantginis, emphasize litigation optionality in the Jemperli dispute with Tesaro and GSK; Piper Sandler has argued the royalty-business separation protects and optimizes that value. The $50-to-$95 spread shows the average analyst price target should be read as a midpoint of plausible outcomes, not a guarantee.
The latest verified closing price is about $49.24, near the lower end of a 52-week range of roughly $20.18 to $72.36. From that level, a move to $75 requires upside of about 53% — a very large move by any standard, especially for a company now valued around $1.45 billion in market capitalization.
Importantly, the $75 target sits just above the stock's 52-week high. Reaching it would require not only a recovery but a breakout to new highs. The stock has already de-rated from its 2026 peak, suggesting investors are demanding more certainty on royalty durability and the litigation timeline before paying up.
Several factors could support a higher stock forecast. The company generates revenue from royalty streams tied to partner products, including GSK's Jemperli, rather than funding its own expensive clinical programs — a lower-cost, cash-generative model after the spinoff. A favorable outcome or settlement in the Jemperli dispute could unlock meaningfully more royalty value, a catalyst several analysts cite. Recent quarters also showed royalty revenue growth, and the company's balance sheet includes substantial cash relative to its size. Analyst sentiment remains broadly positive, with multiple Buy and Overweight ratings and several targets well above the current price.
The principal obstacle is the unresolved litigation. An unfavorable ruling, or a settlement that falls short of expectations, could compress the stock's multiple and pull targets lower — as J.P. Morgan's reduction from $70 to $60 illustrates. Royalty revenue can also be lumpy and dependent on partner commercialization, which AnaptysBio does not control. The stock carries elevated short interest, suggesting a meaningful portion of the market is positioned for downside. Finally, a wide analyst range with a low of $50 means even some bulls see only limited upside from current levels, underscoring that the path to $75 is far from certain.
On a technical basis, the $72.36 52-week high acts as the clearest resistance level, because the central target lies just above it. The stock's pullback toward the high-$40s leaves recent consolidation near $45-to-$50 as a nearer-term support level to watch. The shares also appear technically stretched — one data provider showed a 14-day relative strength index (RSI) near 28, an oversold reading — which can sometimes precede a rebound but does not by itself predict one. A sustained move toward $75 would likely require first reclaiming and holding above prior resistance.
Analyst price targets typically reflect a roughly 12-month research horizon, though firms differ, and none of these targets carries a guarantee. The most important upcoming items are the company's next earnings report (scheduled in early November 2026), any guidance on royalty revenue, and — critically — the oral arguments and expected ruling in the Jemperli litigation, which one analyst noted could land in late 2026 or early 2027. Investors should also watch for target revisions, changes in short interest, and any news on the company's cash position or new royalty transactions.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders spot opportunities, track open positions, and identify changing trends more efficiently than manual screening alone. For a volatile, litigation-driven name like ANAB, automated signal tracking can complement fundamental research by flagging momentum shifts in real time.
Can AnaptysBio reach $75? The central target is a calculated mean of eight analyst price targets, and it implies roughly 53% upside from a price near $49. The strongest supports are a cash-generative royalty model and potential litigation upside, while the principal obstacles are the unresolved Jemperli dispute, royalty visibility, and a wide $50-to-$95 analyst range that signals genuine disagreement. Reaching $75 would require a breakout above the stock's 52-week high — possible if catalysts break favorably, but by no means assured. Investors should weigh the litigation timeline and royalty trajectory rather than treat the $75 figure as a prediction.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ANAB has been loosely correlated with CLRB. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ANAB jumps, then CLRB could also see price increases.
| Ticker / NAME | Correlation To ANAB | 1D Price Change % | ||
|---|---|---|---|---|
| ANAB | 100% | +0.08% | ||
| CLRB - ANAB | 40% Loosely correlated | -0.82% | ||
| QTTB - ANAB | 38% Loosely correlated | -2.31% | ||
| AMRN - ANAB | 38% Loosely correlated | +2.54% | ||
| JBIO - ANAB | 36% Loosely correlated | -0.62% | ||
| LNAI - ANAB | 35% Loosely correlated | -6.65% | ||
More | ||||